FOMO is carrying the day, week and month on Wall Street. And the rally is starting to spread beyond the tech sector.
Vertex dominates the cystic fibrosis market and is dipping its toes in new areas. Moderna's mRNA vaccine platform could lead to major approvals in the coming years.
The market is ignoring Moderna due to its reliance on one product today. But that could be a mistake.
Flagship Pioneering, an investment vehicle helmed by Noubar Afeyan, a co-founder of Moderna and its chairman, bought $12.5 million of shares of biotech Evelo.
Pfizer, Moderna and Novavax have not disclosed the exact pricing of their new vaccines, which will target the circulating omicron subvariant XBB.1.5.
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live co
Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space.
Amazon Prime shopping days are here, and everyone loves good deals, Barron's looked for some in the stock market, and found 15 stocks primed to go higher.

The Perfect 10 Portfolio Is Ready to Roll

10:21am, Monday, 10'th Jul 2023
The phrase “Perfect 10” doesn't just apply to bathing beauties. It's the name of one of my favorite hypothetical stock portfolios.
The Fed has forecast a recession -- but some economists aren't so sure it will happen. It's important to take a long-term view when investing and consider your own investing style.
Moderna, Inc. has submitted multiple regulatory submission of mRNA-1345 as an RSV vaccine in older adults ages 60 and older; additional regulatory submissions expected in coming months. The global res
Shares of pharmaceutical concern Moderna Inc (NASDAQ:MRNA) are 4.3% lower today at $118.25, one day after the company inked a deal to research, develop, and manufacture mRNA medicines in China.
Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.
All three companies are working on updated vaccines for COVID. A new variant, XBB.1.5, led to a spike in COVID cases in China earlier this year.
The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE